Zhaoke Ophthalmology Limited (HKG:6622)

Market Cap	1.10B -35.2%
Revenue (ttm)	40.41M -1.0%
Net Income	-248.16M
EPS	-0.45
Shares Out	547.03M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	45,000
Open	1.985
Previous Close	1.985
Day's Range	1.920 - 2.020
52-Week Range	1.850 - 3.850
Beta	1.15
Analysts	n/a
Price Target	n/a
Earnings Date	Sep 11, 2026

About Zhaoke Ophthalmology

Zhaoke Ophthalmology Limited operates as an ophthalmic pharmaceutical company in Hong Kong, Mainland China, South Korea, and internationally. The company develops Cyclosporine A ophthalmic gel for the treatment of dry eye disease (DED); RGN-259, an eye drop indicated for moderate-to-severe DED; CsA/rebamipide ophthalmic gel for anti-inflammation and tear film stabilization; and IC-265 in Phase II clinical trial for the treatment of allergic conjunctivitis. It also engages in the development of NVK-002, an ophthalmic solution to control or slow ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2017
• Employees: 285
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 6622

Financial Performance

In 2025, Zhaoke Ophthalmology's revenue was 31.97 million, a decrease of -53.88% compared to the previous year's 69.32 million. Losses were -208.98 million, -12.00% less than in 2024.

Financial numbers in CNY

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Nov 3, 2026

Data Sources Report a data error